FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to therapy and cardiology, and can be used for prediction of a risk of acute postinfarction cardiac aneurysm in the patients with acute coronary syndrome with underlying undifferentiated connective tissue dysplasia. Patient’s blood is sampled, blood plasma is examined for the following laboratory values: homocysteine, oxyproline, magnesium. Patient’s blood is examined for low-density lipoproteins, as well as high-density lipoproteins and total cholesterol to calculate an atherogenic index. A probability of developing acute postinfarction cardiac aneurysm for following 14 days is calculated by formula: 
, where: p is the probability of developing acute post-infarction cardiac aneurysm in fractions of one; e is Euler number (constant), equal to 2.71828; z = -374.748 + 1.598 × HC + 4.777 × OP + 374.077 × MG + 2.405 × AI - 13.889 × LDL, where: 374.748 is a constant; 1.598 is the coefficient of the first variable; HC is homocysteine level, mcmol/l; 4.777 is the coefficient of the second variable; OP is level of oxyproline, mcmol/l; 374.077 is the coefficient of the third variable; MG is the level of magnesium, mmol/l; 2.405 is the coefficient of the fourth variable; AI – atherogenicity index, standard units; - 13.889 – coefficient of the fifth variable; LDL – level of low density lipoproteins, mmol/l. If p is less than 0.5, a low risk of acute postinfarction cardiac aneurysm is predicted. If p is not less than 0.5, a high risk of acute postinfarction cardiac aneurysm is predicted.
EFFECT: method provides the effective prediction of the risk of acute postinfarction cardiac aneurysm in the patients with acute coronary syndrome with underlying undifferentiated connective tissue dysplasia by measuring patient’s blood homocysteine, magnesium, oxyproline, atherogenic index and LDL.
1 cl, 2 ex
